Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, is now available for purchase in CVS. With over 7,000 store locations across the United States, CVS is considered the nation's largest pharmacy chain by store count and by retail pharmacy sales per square foot.
“As an over-the-counter, non-narcotic, and non-addictive analgesic, we believe that Cobroxin will become the treatment of choice among those suffering from moderate to severe chronic pain”
"We are excited to announce the availability of Cobroxin in CVS, as this represents the first major drug store chain to carry Cobroxin nationwide," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As an over-the-counter, non-narcotic, and non-addictive analgesic, we believe that Cobroxin will become the treatment of choice among those suffering from moderate to severe chronic pain," he added.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
- All Natural
- Non-Addictive
- Non-Narcotic
- Non-Opiate
- Long Lasting
In 2009, Nutra Pharma granted an exclusive license to XenaCare Holdings (OTCBB: XCHO) to market and distribute Cobroxin in the United States. Recently, XenaCare Holdings announced that Cobroxin will be available for purchase in Walgreens by May 1, 2010.
Telehealth mindfulness interventions significantly improve chronic pain outcomes for veterans